Nate Hardy

Nate Hardy is the Chief Financial Officer of Umoja Biopharma, bringing more than two decades of leadership across corporate finance, investor relations, operations, and strategy experience to Umoja.

Most recently, Nate served as Chief Financial Officer at ArsenalBio, a clinical-stage solid tumor cell therapy company, where he led the strategic planning, accounting, IT organization and oversaw the investment and resource allocation strategy of a $325M fundraise to advance both its clinical and preclinical pipeline development. Prior to ArsenalBio, he served as the founding CFO and Executive Vice President of Sana Biotechnology, an allogeneic and novel cell therapy company, overseeing Sana’s $700M initial private fundraise through its $675M IPO and successive fundraises along with leading the finance and IT organizations. Prior to Sana, Nate held leadership roles in finance at Juno Therapeutics, Amgen, and multiple other Fortune 500 public companies.

Nate earned a Bachelor of Science in Finance from the University of Utah and an MBA from the University of Notre Dame’s Mendoza College of Business.